Korean FDA approves Phase I clinical trial for VM202
ViroMed today announced Korean FDA approval of a Phase I clinical trial for VM202 – ViroMed’s leading gene therapy treatment candidate for cardiovascular disease.
What is VM202
VM202 consists of ViroMed’s proprietary pCK vector encoding the genetically engineered hepatocyte growth factor (HGF) gene for the treatment of patients with ischemic disease, including coronary artery disease and peripheral artery disease. VM202 was engineered to express two isoforms of HGF protein in a highly efficient manner. Treatment is directed at restoration of blood flow to affected areas through regenerative angiogenesis.
ViroMed is planning to conduct its clinical trial at the Seoul National University Hospital, Korea.